Annexon (ANNX) Stock Forecast, Price Target & Predictions
ANNX Stock Forecast
Annexon stock forecast is as follows: an average price target of $14.00 (represents a 167.69% upside from ANNX’s last price of $5.23) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ANNX Price Target
The average price target for Annexon (ANNX) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 167.69% upside from ANNX's last price of $5.23.
ANNX Analyst Ratings
According to 5 Wall Street analysts, Annexon's rating consensus is 'Buy'. The analyst rating breakdown for ANNX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Annexon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 05, 2024 | Derek Archila | Wells Fargo | $14.00 | $5.99 | 133.72% | 167.69% |
| May 15, 2024 | Derek Archila | Wells Fargo | $10.00 | $4.82 | 107.47% | 91.20% |
| Apr 01, 2024 | Derek Archila | Wells Fargo | $12.00 | $7.17 | 67.36% | 129.45% |
The latest Annexon stock forecast, released on Jun 05, 2024 by Derek Archila from Wells Fargo, set a price target of $14.00, which represents a 133.72% increase from the stock price at the time of the forecast ($5.99), and a 167.69% increase from ANNX last price ($5.23).
Annexon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $5.23 | $5.23 | $5.23 |
| Upside/Downside | -100.00% | -100.00% | 129.45% |
In the current month, the average price target of Annexon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Annexon's last price of $5.23. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 06, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 26, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 05, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 15, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Dec 21, 2023 | Bank of America Securities | Buy | Upgrade | |
| Sep 16, 2022 | Jefferies | Buy | Initialise | |
| Nov 30, 2021 | H.C. Wainwright | Buy | Initialise |
Annexon's last stock rating was published by Cowen & Co. on Oct 23, 2024. The company gave ANNX a "Buy" rating, the same as its previous rate.
Annexon Financial Forecast
Annexon Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Annexon's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANNX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Annexon EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ANNX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Annexon's previous annual EBITDA (undefined) of $NaN.
Annexon Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-40.49M | $-39.65M | $-38.80M | $-36.96M | $-37.72M | $-36.12M | $-29.86M |
| High Forecast | $-40.49M | $-39.65M | $-38.80M | $-35.69M | $-35.03M | $-36.12M | $-29.86M |
| Low Forecast | $-40.49M | $-39.65M | $-38.80M | $-38.24M | $-44.46M | $-36.12M | $-29.86M |
| Surprise % | - | - | - | - | - | - | - |
Annexon's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANNX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Annexon SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Annexon's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANNX last annual SG&A of $NaN (undefined).
Annexon EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.26 | $-0.27 | $-0.26 | $-0.23 |
| High Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.26 | $-0.25 | $-0.26 | $-0.23 |
| Low Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.27 | $-0.32 | $-0.26 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Annexon's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANNX previous annual EPS of $NaN (undefined).
Annexon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| IMMX | Immix Biopharma | $2.29 | $7.00 | 205.68% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
| RCUS | Arcus Biosciences | $16.08 | $31.71 | 97.20% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| WVE | Wave Life Sciences | $14.45 | $22.14 | 53.22% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |